Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: MELI stock price vs HRMY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at HRMY's multiple
Needs HRMY P/E.
Implied fair value · at MELI's multiple
Needs MELI P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: MELI FY 2025 (ended Dec 31, 2025) · HRMY FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 92% equity / 8% debt · EV / Revenue 3.57x · EV / EBITDA 29.81x
Capital structure 94% equity / 6% debt · EV / Revenue 2.13x · EV / EBITDA 7.28x
MELI carries the larger enterprise value at $103.19B against $1.85B; HRMY trades on the lower EV / Revenue multiple (2.13x vs 3.57x); HRMY on the lower EV / EBITDA (7.28x vs 29.81x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
MercadoLibre, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
HARMONY BIOSCIENCES HOLDINGS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.36x
0.19x
Net debt / EBITDA
Leverage against operating earnings
0.84x
-2.41x
Cash and equivalents
Liquid reserves on the balance sheet
$6.30B
$775.34M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMAZON COM INC
MELI vs AMZN
DoorDash, Inc.
MELI vs DASH
Sea Ltd
MELI vs SE
EBAY INC
MELI vs EBAY
PDD Holdings Inc.
MELI vs PDD
JD.com, Inc.
MELI vs JD
Jazz Pharmaceuticals plc
MELI vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
MELI vs SUPN
Intra-Cellular Therapies, Inc.
MELI vs ITCI
ACADIA PHARMACEUTICALS INC
MELI vs ACAD
Vanda Pharmaceuticals Inc.
MELI vs VNDA
LivaNova PLC
MELI vs LIVN
$9.19B
$163.66M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
